Skip to main content

Clinical Trial News & Results

This section provides information about recently completed clinical trials. If you cannot find information about a particular clinical trial, you should note that results may not be available even after the trial ends. Some trials end before completion and results are never published.

First Patients Enrolled in US Pivotal Study of AI-Based Image Analysis Module for Lung Cancer

SANTA CLARA, Calif., Aug. 9, 2024. Invenio Imaging, a leader in intraoperative fresh tissue imaging and artificial intelligence (AI), announced today the...

WestGene to Advance Clinical Trials Following Dual IND Approvals for World's First EB Virus-Related mRNA Therapeutic Cancer Vaccine

CHENGDU, China, Aug. 8, 2024. WestGene Biopharma is proud to announce that its mRNA therapeutic cancer vaccine, WGc-043, has received dual IND approvals from...

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap

LEXINGTON, Mass.--(BUSINESS WIRE)--Aug. 8, 2024-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and...

Merck Provides Update on Phase 3 KeyVibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With Extensive-Stage Small Cell Lung Cancer

RAHWAY, N.J.--(BUSINESS WIRE) August 8, 2024 --Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the discontinuation...

Groundbreaking Nipocalimab Study of Pregnant Individuals at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn Published in The New England Journal of Medicine

SPRING HOUSE, Pa., (August 7, 2024) – Johnson & Johnson today announced the results from the Phase 2 open-label UNITY study of nipocalimab for the...

Turn Therapeutics Topical Atopic Dermatitis Candidate Significantly Inhibits Key Cytokines in Expansion Study of Flagship Formula

WESTLAKE VILLAGE, Calif., Aug. 5, 2024. Turn Therapeutics, a pharmaceutical and medical device company focused on immunology, advanced wound care, and...

Innovent and SanegeneBio Announce First Participant Dosed in a Phase 1 Clinical Trial of IBI3016

SAN FRANSCISO and SUZHOU, China, Aug. 1, 2024. Innovent Biologics, Inc. ("Innovent"), a world-class biopharmaceutical company that develops, manufactures and...

IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients With Relapsed Small Cell Lung Cancer

BASKING RIDGE, N.J. & RAHWAY, N.J., August 1, 2024 – Daiichi Sankyo (TSE: 4568) and Merck (NYSE: MRK), known as MSD outside of the United States and...

BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma

MAINZ, Germany, July 30, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced positive...

Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Efficacy, Safety and Tolerability of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia

Florence, Italy; 29th July, 2024 – Menarini Group today announces positive topline data from the Phase 3 BROOKLYN clinical trial (NCT05425745) sponsored...

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference(R) 2024 (AAIC(R))

SOUTH SAN FRANCISCO, Calif., July 28, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering...

NIH Researchers Discover Potential Therapeutic Target for Degenerative Eye Disease

July 26, 2024 -- Researchers from the National Institutes of Health (NIH) have discovered the source of dysfunction in the process whereby cells in the eye's...

Presage Biosciences Announces First Patient Dosing of Pure Biologics' ROR1 Targeting Antibody For Treatment of Cancer

SEATTLE, July 25, 2024. Presage Biosciences, a biotechnology company that directly measures activity of oncology drugs within human tumors, announced the Phase...

Final Results from a Phase 2 Study of TPN-101 for the Treatment of C9orf72-Related Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia

SAN DIEGO, July 24, 2024. Transposon Therapeutics, a biotechnology company developing a platform of novel, orally administered therapies for the treatment of...

Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor

CAMBRIDGE Mass. –July 24, 2024 – Sage Therapeutics, Inc. (NASDAQ: Sage) and Biogen Inc. (NASDAQ: BIIB) announced topline results from the Phase 2...

Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate Giroctocogene Fitelparvovec

NEW YORK--(BUSINESS WIRE) July 24, 2024 -- Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 AFFINE study (NCT04370054)...

Vivacelle Bio Initiates Phase 3 Trial for Lead Asset VBI-S to Treat Patients with Hypovolemia Due to Septic Shock

KANSAS CITY, Mo., July 23, 2024. Vivacelle Bio, a late-stage biopharma company developing life-saving treatments for shock and trauma, today announced the...

ConSynance Therapeutics Receives FDA Rare Pediatric Disease Designation for CSTI-500 in Prader-Willi Syndrome

RENSSELAER, N.Y., July 24, 2024 (GLOBE NEWSWIRE) -- ConSynance Therapeutics, Inc., a clinical-stage biopharmaceutical company developing first-in-class...

An Isolated Viral Load Test May Generate False Positive Results for People Using Long-Acting PrEP

July 23, 2024 -- A single laboratory-based HIV viral load test used by U.S. clinicians who provide people with long-acting, injectable cabotegravir (CAB-LA)...

Long-Acting Injectable Cabotegravir for HIV Prevention is Safe in Pregnancy

July 23, 2024 -- Long-acting injectable cabotegravir (CAB-LA) was safe and well tolerated as HIV pre-exposure prophylaxis (PrEP) before and during pregnancy in...

View older articles

Clinical trial results archive

2024
January, February, March, April, May, June, July, August
2023
January, February, March, April, May, June, July, August, September, October, November, December
2022
January, February, March, April, May, June, July, August, September, October, November, December
2021
January, February, March, April, May, June, July, August, September, October, November, December
2020
January, February, March, April, May, June, July, August, September, October, November, December
2019
January, February, March, April, May, June, July, August, September, October, November, December
2018
January, February, March, April, May, June, July, August, September, October, November, December
2017
May, June, July, August, September, October, November, December
2016
October

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of drugclasses.com in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Stay up-to-date
Recently Approved
  • neffy

    neffy® (epinephrine) is an intranasal epinephrine formulation for the emergency...

  • Enzeevu

    Enzeevu (aflibercept-abzv) is a vascular endothelial growth factor (VEGF)...

  • Yorvipath

    Yorvipath (palopegteriparatide) is a parathyroid hormone analog (PTH(1-34))...

More drug approvals